Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at Wedbush in a note issued to investors on Monday,Benzinga reports. They currently have a $12.00 price objective on the stock. Wedbush’s target price would suggest a potential downside of 11.03% from the stock’s previous close.
Several other analysts also recently weighed in on NTLA. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, March 2nd. Canaccord Genuity Group decreased their price objective on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. restated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Finally, Morgan Stanley raised their target price on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.46.
View Our Latest Analysis on NTLA
Intellia Therapeutics Stock Performance
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the prior year, the company earned ($1.10) earnings per share. As a group, analysts predict that Intellia Therapeutics will post -3.18 EPS for the current year.
Hedge Funds Weigh In On Intellia Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. Comerica Bank increased its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics during the 2nd quarter worth $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $33,000. Finally, Spire Wealth Management purchased a new stake in shares of Intellia Therapeutics in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Featured Stories
- Five stocks we like better than Intellia Therapeutics
- Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
- Mission Control: Floating In SpaceX’s Record-Breaking Orbit
- Forget AI for a Moment, This Homebuilder Is Stealing the Show
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
